Cover Image
市場調查報告書

世界治療用脂類調節器市場:製品、產品管道分析

Product and Pipeline Analysis of the Global Therapeutic Lipid Modulators Market

出版商 Frost & Sullivan 商品編碼 306534
出版日期 內容資訊 英文 72 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
世界治療用脂類調節器市場:製品、產品管道分析 Product and Pipeline Analysis of the Global Therapeutic Lipid Modulators Market
出版日期: 2014年06月20日 內容資訊: 英文 72 Pages
簡介

世界各地目前有許多各式各樣的脂類異常症患者存在。多數患者可靠著現在醫療水準治療、但由於治療方法可能不適當或不完全正在努力開發創新的治療藥物。

本報告針對全世界治療用脂類調節器市場已上市/開發中產品管道製品進行分析、市場背景、整體開發進行狀況、主要上市製品與測試最終階段製品詳細內容。

第1章 摘要整理

第2章 分析方法、範圍

第3章 介紹

第4章 市場背景

  • 脂類、脂肪蛋白概要
  • 主要國家膽固醇過高的患者數
  • 美國低密度膽固醇過高患者數與管理方法
  • 脂肪蛋白等級分類
  • 先天性血脂異常分類
  • ACC/AHA治療法指南
  • 歐洲式治療指南
  • 市場詳細

第5章 競爭環境

  • 已上市/產品管道製品數量
  • 競爭環境:已上市製品與開發中製品
  • 已上市製品分析
  • 產品管道製品分析
  • 製品上市預定表
  • 專利到期預定表
  • 第III期治療計畫
    • Evolocumab (Amgen)
    • Alirocumab (Sanofi/Regeneron)
    • Bococizumab (Pfizer)
  • 效能比較分析

第6章 近年上市與尚在測試最終階段的產品檔案

  • Kynamro(mipomersen sodium)
  • Juxtapid/Lojuxta(lomitapide)
  • Vascepa(icosapent ethyl)
  • Evolocumab (AMG145)
  • Alirocumab (REGN727)
  • Bococizumab (RN316)

第7章 結論與建議

  • 結論與建議
  • 法律免責事項

第8章 附錄

目錄
Product Code: NDDD-01-00-00-00

Relentless Pursuit of Blockbuster Cardiovascular Therapeutics

Dyslipidemia exists in many forms and is prevalent in developed regions. Although many patients with moderately elevated lipids are well served by available therapies, there is a significant patient population for whom these therapies are inappropriate or inadequate, thereby prompting development of innovative therapies to fill the gaps. This research service includes comprehensive information on the market background, analyses of drug development, detailed product and pipeline analyses, detailed product profiles for key marketed/late-stage products, and a global overview. The research service also provides time-sensitive details such as new product launch timelines, PCSK9 Phase 3 programs, and patent expirations.

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • 1. Executive Summary
  • 2. Executive Summary (continued)
  • 3. Recent Market Developments
  • 4. Defining Healthcare Trends in the Future
  • 5. Companies to Watch

2. METHODOLOGY AND SCOPE

Methodology and Scope

  • 1. Methodology and Scope

3. INTRODUCTION

Introduction

  • 1. Introduction

4. MARKET BACKGROUND

Market Background

  • 1. Lipid and Lipoprotein Basics
  • 2. Prevalence of Elevated Cholesterol in Major Markets
  • 3. Prevalence of Elevated Cholesterol in Major Markets (continued)
  • 4. Prevalence and Management of Elevated LDL-C in the United States
  • 5. Classification of Lipoprotein Levels
  • 6. Classification of Familial Dyslipidemias
  • 7. ACC/AHA Practice Guidelines
  • 8. ACC/AHA Practice Guidelines (continued)
  • 9. ACC/AHA Practice Guidelines (continued)
  • 10. European Practice Guidelines
  • 11. Market Segmentation
  • 12. Market Segmentation (continued)
  • 13. Market Segmentation (continued)

5. COMPETITIVE LANDSCAPE

Competitive Landscape

  • 1. Competitive Landscape-Number of Marketed and Pipeline Products
  • 2. Competitive Landscape-Marketed and Pipeline Products
  • 3. Marketed Product Analysis
  • 4. Marketed Product Analysis (continued)
  • 5. Marketed Product Analysis (continued)
  • 6. Marketed Product Analysis (continued)
  • 7. Marketed Product Analysis (continued)
  • 8. Marketed Product Analysis (continued)
  • 9. Marketed Product Analysis (continued)
  • 10. Pipeline Analysis
  • 11. Pipeline Analysis-Products in Clinical Development (continued)
  • 12. Pipeline Analysis-Products in Clinical Development (continued)
  • 13. Pipeline Analysis-Products in Clinical Development (continued)
  • 14. Pipeline Analysis-Products in Clinical Development (continued)
  • 15. Pipeline Analysis-Products in Clinical Development (continued)
  • 16. Pipeline Analysis-Products in Clinical Development (continued)
  • 17. Product Launch Timeline
  • 18. Patent Expiration Timeline
  • 19. Phase 3 Clinical Program-Evolocumab (Amgen)
  • 20. Phase 3 Data Readouts-Evolocumab (Amgen)
  • 21. Phase 3 Clinical Program-Alirocumab (Sanofi/Regeneron)
  • 22. Phase 3 Clinical Program-Bococizumab (Pfizer)
  • 23. Comparative Efficacy Analysis
  • 24. Comparative Efficacy Analysis Discussion

6. PROFILES OF RECENTLY LAUNCHED AND LATE-STAGE INVESTIGATIONAL PRODUCTS

Profiles of Recently Launched and Late-stage Investigational Products

  • 1. Product Dashboard-Kynamro (mipomersen sodium)
  • 2. Product Dashboard-Juxtapid/Lojuxta (lomitapide)
  • 3. Product Dashboard-Vascepa (icosapent ethyl)
  • 4. Product Dashboard-Evolocumab (AMG145)
  • 5. Product Dashboard-Alirocumab (REGN727)
  • 6. Product Dashboard-Bococizumab (RN316)

7. CONCLUSIONS AND RECOMMENDATIONS

Conclusions and Recommendations

  • 1. Conclusions and Recommendations
  • 2. Legal Disclaimer

8. THE FROST & SULLIVAN STORY

The Frost & Sullivan Story

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top